Literature DB >> 10546941

Safety of repeated intravitreous injections of antibiotics and dexamethasone.

M O Yoshizumi1, A R Bhavsar, A Dessouki, A Kashani.   

Abstract

PURPOSE: To determine the retinotoxicity of repeated intravitreous injections of vancomycin, ceftazidime, and dexamethasone in rabbit eyes.
METHODS: Twenty pigmented New Zealand rabbits were divided into two groups. In Group 1, the right eyes received repeated intravitreous injections with vancomycin 0.3 mg, ceftazidime 0.7 mg, and dexamethasone sodium phosphate 0.13 mg at three consecutive 48-hour intervals. Group 2 right eyes received three times higher dose of the same intravitreous drugs as used in Group 1, repeated at the same frequency. All left eyes served as control eyes. Retinotoxicity was monitored by slit-lamp biomicroscopy, indirect ophthalmoscopy, electroretinography, and light and electron microscopy.
RESULTS: No evidence of retinotoxicity was found in Group 1 eyes. Photopic A-waves were significantly elevated, and 30- and 50-Hz flicker fusion amplitudes were significantly depressed in Group 2 eyes. No changes were found by clinical or histopathologic examination in the retinas of either group.
CONCLUSIONS: Three repeated intravitreous injections at 48-hour intervals of a combination of vancomycin, ceftazidime, and dexamethasone in rabbit eyes at dosages that approximate drug concentrations recommended for human endophthalmitis were nontoxic. Similar injections at three times higher doses resulted in mild electroretinogram changes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546941     DOI: 10.1097/00006982-199909000-00012

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits.

Authors:  Fabio Gasparin; Renata Genaro Aguiar; Gabriela Lourençon Ioshimoto; Armando Silva-Cunha; Silvia Ligório Fialho; André Mauricio Liber; Balázs Vince Nagy; Nestor Norio Oiwa; Marcelo Fernandes Costa; Christina Joselevitch; Dora Fix Ventura; Francisco Max Damico
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-14       Impact factor: 2.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.